BeOne Medicines-linked "High Five" Phase 3 NSCLC trial registered, not yet recruiting
A newly listed Phase 3 study will test whether adding chemotherapy to tislelizumab helps high-PD-L1, high-tumor-burden metastatic NSCLC patients, per ClinicalTrials.gov.
This week's filing covers one newly registered late-stage lung cancer study tied to tislelizumab.
- "High Five" (NCT07715396, sponsor ID AIO-TRK/YMO-0425) is a randomized, open-label Phase 3 trial comparing immunotherapy alone against immunotherapy plus platinum-based chemotherapy in patients with metastatic non-small cell lung cancer who have high PD-L1 expression of at least 50% and a high tumor burden defined as a baseline tumor size of at least 50 mm1. The lead sponsor is AIO-Studien-gGmbH, with BeOne Medicines1 listed as a collaborator. The study is not yet recruiting, with an estimated enrollment of 230 participants1, and its estimated start date is October 30, 2026. The primary endpoint is progression-free survival, measured as time from randomization to first objective disease progression per RECIST v1.1 by blinded independent central review, or death from any cause1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.